|On the cover: On the cover: Nourished by the gigantic data and empowered by increasing computing facilities, Artificial Intelligence (AI) is setting us free from many burdensome routines. With AI muscles, we have become faster and smarter than ever. AI is reshaping the future of industries and our lives, enabling paradigm shifts in many disciplines of science and even paving the road to the metaverse. But scientists are still facing endless choices to navigate their innovation processes as previously. Meanwhile, collaborations are urgently needed amongst researchers from multidisciplinary studies. So we do hope the shared values of truth, righteousness, and peace can be cherished deeply to make our blue planet a better place for the whole ecosystem.|
|Add comment (English only)|
|Position: Home > issue > November 28, 2021 Volume 2, Issue 4|
|Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination?|
Mechanism of action of favipiravir against SARS-CoV-2
Favipiravir is a novel broad-spectrum antiviral drug against RNA viruses that has been approved for the treatment of seasonal and pandemic influenza. The use of favipiravir is a potential therapeutic approach to SARS-CoV-2 infection; several clinical trials have shown that favipiravir could effectively improve the clinical recovery and/or viral RNA clearance of patients, with proven safety profiles.1,2 Favipiravir is a prodrug and its active form, favipiravir ribofuranosyl-triphosphate (FTP), inhibits viral replication by targeting the RNA-dependent RNA polymerase (RdRp).
Zhao L., Zhong W. (2021). Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination? The Innovation. 2(4),100165.